Mumbai: Pharma major Lupin Ltd said on Friday it has got an establishment inspection report (EIR) from the US Food and Drug Administration for its Aurangabad facility.
“This takes us a step forward in our efforts of enhancing our compliance and quality standards across all our manufacturing sites,” said Managing Director Nilesh Gupta.
“We continue to work with the US FDA to continuously improve our quality and compliance while providing important medicines to the US market,” he said in a statement.
The inspection for Aurangabad facility was carried out between February 10 and 14, and concluded with no observations.
“We are delighted with the receipt of EIR for Aurangabad classifying the inspection as ‘no action indicated.’
